A Phase 3 interventional study of Selexipag and Placebo in Chronic Thromboembolic Pulmonary Hypertension, sponsored by Actelion. Terminated at 162 sites in 31 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-06-21.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Hypertension, Pulmonary by Johnson & Johnson — 1 open to participants now, 2 under way, 2 of them phase 3. Hypertension, Pulmonary · Johnson & Johnson.
Among the 29 studies in Hypertension, Pulmonary by Johnson & Johnson, this one is the 9th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2019, is one of 13 in phase 3, and was the 21st registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →1 of the 29 studies in Hypertension, Pulmonary by Johnson & Johnson is open now, in 12 countries. Recruiting first, the newest first:
Actelion · Sites in Belarus, Belgium, Bulgaria and 10 more countries
Ages 2+
By country, each count listing its studies:
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 128 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 67 across the 27 interventional studies, 2,003 across the 2 observational. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
1 of the studies in Hypertension, Pulmonary by Johnson & Johnson that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Hypertension, Pulmonary by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other PAH medicines in CTEPH, it is believed that selexipag could benefit to patients with CTEPH. This study aims to assess the efficacy and safety of selexipag in participants with inoperable or persistent/recurrent CTEPH.
Participants will be recruited in two sequential cohorts: approximately the first 90 randomized participants will undergo a right heart catheterization (RHC) (and left heart catheterization LHC, if needed) with measurement of pulmonary vascular resistance (PVR) at Week 20 and will constitute the hemodynamic cohort; the remaining participants will constitute the non-hemodynamic cohort; who do not require a post-baseline hemodynamic assessment. They will undergo the same overall study assessments as the hemodynamic cohort excepted for RHC at Week 20.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the double blind treatment period, participants in this group will receive selexipag. Each participant will start with one oral tablet of selexipag 200 µg in the evening of Day 1 and will continue with 200 µg twice daily (b.i.d.) on Day 2. If this dose is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg until reaching the individual maximal tolerated dose (iMTD) in the range of 200 to 1600 µg b.i.d. The up-titration period up to Week 12 is followed by a stable maintenance treatment period from Week 12 to Week 26, at the iMTD. After Week 26, further up-titration can be allowed (but not above 1600 µg b.i.d.).
Drug: Selexipag
During the double-blind treatment period, participants in this group will receive the oral matching placebo, twice daily. A (mock) up-titration scheme will be followed.
Drug: Placebo
All participants who completed the double-blind treatment period, whether they received placebo or selexipag during the double-blind period, will receive selexipag during the open-label extension period, using the same up-titration schedule as in the double-blind period.
Drug: Selexipag
oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 to 8 tablets at each administration
Also known as: ACT-293987, JNJ-67896049
Oral tablets without active compound
Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 20
Change from baseline in PVR at Week 20 was reported. PVR was measured by accessing the vessel either from right heart catheterization or left heart catheterization, if required. Change from baseline in PVR was measured as percent ratio of post treatment value (Week 20) to pre-treatment value (baseline).
Time frame: Baseline (Day 1, pre-dose), within 2 to 5 hours post-dose on Week 20
| Milestone | Double-blind Period: Placebo | Double-blind Period: Selexipag | Open Label Period: Selexipag (Ex-Placebo) | Open Label Period: Selexipag (Ex-Selexipag) |
|---|---|---|---|---|
| Started | 64 | 64 | 0 | 0 |
| Completed | 9 | 6 | 0 | 0 |
| Not completed | 55 | 58 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 8 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 0 | 0 |
| Withdrew: Sponsor decision | 44 | 47 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 2 | 0 | 0 |
| Milestone | Double-blind Period: Placebo | Double-blind Period: Selexipag | Open Label Period: Selexipag (Ex-Placebo) | Open Label Period: Selexipag (Ex-Selexipag) |
|---|---|---|---|---|
| Started | 0 | 0 | 9 | 6 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 9 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 7 | 6 |
Change from baseline in PVR at Week 20 was reported. PVR was measured by accessing the vessel either from right heart catheterization or left heart catheterization, if required. Change from baseline in PVR was measured as percent ratio of post treatment value (Week 20) to pre-treatment value (baseline).
| Percent ratio | Double-blind Period: Placebo | Double-blind Period: Selexipag |
|---|---|---|
| Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 20 | 89.52 (81.78 to 97.99) | 85.15 (77.97 to 92.99) |
Collected over For DB period: from first DB dose up to EDBT (that is, up to 27.7 months) and for OL extension period: from first OL dose up to 30 days after the last OL dose (that is, up to 21.8 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Period: Placebo | 2/64 (3.1%) | 16/64 (25%) | 45/64 (70.3%) |
| Double-blind Period: Selexipag | 3/64 (4.7%) | 9/64 (14.1%) | 60/64 (93.8%) |
| Open Label Period: Selexipag (Ex-Placebo) | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Open Label Period: Selexipag (Ex-Selexipag) | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Event | Double-blind Period: Placebo | Double-blind Period: Selexipag | Open Label Period: Selexipag (Ex-Placebo) | Open Label Period: Selexipag (Ex-Selexipag) |
|---|---|---|---|---|
| Viral InfectionInfections and infestations | 0/64 | 0/64 | 0/9 | 1/6 |
| Right Ventricular FailureCardiac disorders | 3/64 | 5/64 | 0/9 | 0/6 |
| Acute Kidney InjuryRenal and urinary disorders | 2/64 | 1/64 | 0/9 | 0/6 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 2/64 | 0/64 | 0/9 | 0/6 |
| Iron Deficiency AnaemiaBlood and lymphatic system disorders | 0/64 | 1/64 | 0/9 | 0/6 |
| Atrial FlutterCardiac disorders | 1/64 | 0/64 | 0/9 | 0/6 |
| Atrioventricular Block Second DegreeCardiac disorders | 1/64 | 0/64 | 0/9 | 0/6 |
| Supraventricular TachycardiaCardiac disorders | 0/64 | 1/64 | 0/9 | 0/6 |
| Discoloured VomitGastrointestinal disorders | 1/64 | 0/64 | 0/9 | 0/6 |
| Catheter Site HaematomaGeneral disorders | 1/64 | 0/64 | 0/9 | 0/6 |
| Event | Double-blind Period: Placebo | Double-blind Period: Selexipag | Open Label Period: Selexipag (Ex-Placebo) | Open Label Period: Selexipag (Ex-Selexipag) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 14/64 | 36/64 | 6/9 | 2/6 |
| DiarrhoeaGastrointestinal disorders | 9/64 | 38/64 | 5/9 | 1/6 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/64 | 7/64 | 4/9 | 0/6 |
| NauseaGastrointestinal disorders | 4/64 | 17/64 | 3/9 | 1/6 |
| VomitingGastrointestinal disorders | 1/64 | 11/64 | 3/9 | 1/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/64 | 14/64 | 3/9 | 1/6 |
| Pain in JawMusculoskeletal and connective tissue disorders | 2/64 | 16/64 | 2/9 | 0/6 |
| Covid-19Infections and infestations | 4/64 | 5/64 | 2/9 | 0/6 |
| DizzinessNervous system disorders | 7/64 | 8/64 | 2/9 | 0/6 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 4/64 | 13/64 | 1/9 | 1/6 |
| Age, Categorical(Participants) | Double-blind Period: Placebo | Double-blind Period: Selexipag | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 24 | 36 | 60 |
| >=65 years | 40 | 28 | 68 |
| Age, Continuous(years) | Double-blind Period: Placebo | Double-blind Period: Selexipag | Total |
|---|---|---|---|
| Mean | 64 ± 13.22 | 62 ± 14.38 | 63 ± 13.8 |
| Sex: Female, Male(Participants) | Double-blind Period: Placebo | Double-blind Period: Selexipag | Total |
|---|---|---|---|
| Female | 47 | 46 | 93 |
| Male | 17 | 18 | 35 |
| Ethnicity (NIH/OMB)(Participants) | Double-blind Period: Placebo | Double-blind Period: Selexipag | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 8 | 18 |
| Not Hispanic or Latino | 54 | 55 | 109 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Double-blind Period: Placebo | Double-blind Period: Selexipag | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 12 | 7 | 19 |
| Black or African American | 3 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 46 | 52 | 98 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Other | 2 | 2 | 4 |
| Region of Enrollment(Participants) | Double-blind Period: Placebo | Double-blind Period: Selexipag | Total |
|---|---|---|---|
| ARGENTINA | 0 | 2 | 2 |
| AUSTRALIA | 1 | 3 | 4 |
| BELGIUM | 0 | 1 | 1 |
| BRAZIL | 5 | 6 | 11 |
| BULGARIA | 1 | 3 | 4 |
| CANADA | 0 | 1 | 1 |
| CHINA | 0 | 2 | 2 |
| CZECH REPUBLIC | 1 | 2 | 3 |
| DENMARK | 4 | 3 | 7 |
| GERMANY | 6 | 9 | 15 |
| HUNGARY | 0 | 1 | 1 |
| ISRAEL | 2 | 0 | 2 |
| ITALY | 2 | 3 | 5 |
| MEXICO | 4 | 1 | 5 |
| POLAND | 2 | 2 | 4 |
| PORTUGAL | 5 | 1 | 6 |
| RUSSIAN FEDERATION | 4 | 3 | 7 |
| SLOVAKIA | 0 | 1 | 1 |
| SOUTH KOREA | 7 | 2 | 9 |
| SPAIN | 1 | 0 | 1 |
| SWEDEN | 0 | 1 | 1 |
| TAIWAN | 1 | 1 | 2 |
| THAILAND | 4 | 2 | 6 |
| TURKEY | 4 | 4 | 8 |
| UKRAINE | 0 | 1 | 1 |
| UNITED KINGDOM | 5 | 6 | 11 |
| UNITED STATES | 5 | 3 | 8 |
Showing the first 100 of 162 sites across 31 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Actelion is a Janssen pharmaceutical company of Johnson \& Johnson. The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials\transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Jan 2019 to primary completion in Jun 2022, 40 months.
Results were first posted in Aug 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selexipag